Gut microbiota in patients undergoing hemodialysis and the effect of synbiotic therapy on its composition
- 29 June 2026
- journal article
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 28 (2)
Abstract
Introduction . Growing evidence highlights the critical role of the gut microbiota in human health, homeostasis, and disease development and progression. The gut-kidney axis plays a pivotal role in mediating the interaction between the gut microbiota and renal function. Dysbiosis and progressive biochemical alterations within the intestinal milieu contribute to chronic inflammation and increased intestinal permeability. The systemic translocation of toxic microbial metabolites, particularly uremic toxins, may result in damage to multiple organ systems, including the kidneys. Currently, data on the gut microbiota and its metabolites in patients undergoing hemodialysis, as well as on the effects of symbiotic therapy in this population, remains limited and often conflicting. Methods. The prospective cohort study included 26 patients receiving standard, adequate hemodialysis three times weekly. Gut microbiota samples were collected and analysed at two time points: before initiation of symbiotic therapy, and after months of treatment. Microbial composition was assessed using 16S rRNA sequencing followed by bioinformatic analysis. Results. Synbiotics therapy significantly affected the alpha and beta diversity of the gut microbiota in patients undergoing hemodialysis. Significant changes in alpha-diversity indices were observed following treatment, with decreases in both the Shannon and Chao1 indices. Analysis of beta diversity demonstrated a significant shift in microbial community composition after completion of symbiotic therapy. Specifically, the Bray-Curtis dissimilarity index revealed significant clustering of post-treatment samples. Although baseline microbiota profiles were relatively similar among patients, microbial community dispersion increased substantially following the intervention. Synbiotic therapy was associated with relative abundances of the families Lactobacillaceae and Veillonellaceae, whereas abundancies of the families Anaerovoracaceae and Acidaminococcaceae decreased. These changes were accompanied by reduction in the relative abundance of [Ruminococcus] gnavus, [Ruminococcus] gauvreauii, Phascolarctobacterium, and Sutterella. Conclusion . The observed changes in the gut microbiota composition following symbiotic therapy are complex and difficult to interpret definitely. Nevertheless, we believe that synbiotics administration may promote favorable alternations in the interstinal microbial community. A comprehensive assessment of the clinical significance of these changes should incorporate analyses of circulating metabolites and patient outcomes. Further studies are needed to clarify the effects of synbiotics on the gut microbiota and their potential therapeutic implications in patients undergoing hemodialysis.Keywords
This publication has 28 references indexed in Scilit:
- Lactic acid bacteria target NF-κB signaling to alleviate gastric inflammationFood & Function, 2025
- Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021The Lancet, 2024
- Analysis of intestinal flora and cognitive function in maintenance hemodialysis patients using combined 16S ribosome DNA and shotgun metagenome sequencingAging Clinical and Experimental Research, 2024
- A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseasesKidney International, 2019
- Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolismNature Medicine, 2019
- Diversity-disease relationships and shared species analyses for human microbiome-associated diseasesThe ISME Journal, 2019
- Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territoriesThe Lancet, 2018
- Meta-analysis of gut microbiome studies identifies disease-specific and shared responsesNature Communications, 2017
- A reduction in the butyrate producing species Roseburia spp. and Faecalibacterium prausnitzii is associated with chronic kidney disease progressionAntonie van Leeuwenhoek, 2016
- The intestinal microbiota, a leaky gut, and abnormal immunity in kidney diseaseKidney International, 2013